They were having discussions with FDA on the possibility of accelerated approval for SRP-9001 (which has shown DMD treatment efficacy in Phase 2 trials) since April. Most analysts didn’t give them much chance (still to complete phase 3). Then on July 29th they went into a trading halt at circa $85 and announced that will formally apply for accelerated approval, which meant that talks with the FDA had been positive.
The stock rose 33% to circa $114 in the 7 days after trading resumed.
I got this off publicly available announcements, not because I work for Sarepta (attn. Monti, RYN etc. lol)
ANP Price at posting:
8.6¢ Sentiment: Hold Disclosure: Held
